Emerging new therapies in rheumatoid arthritis: What's next for the patient?

Journal of Infusion Nursing

Volumn 29, Issue 6, 2006, Pages 326-337

  Leff, Linda ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Association of Rheumatology Health Professionals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

BIOLOGICAL THERAPY; BLOOD DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INFUSION NURSE; INJECTION SITE REACTION; INNATE IMMUNITY; LIVER DYSFUNCTION; LIVER INJURY; LYMPHOMA; NURSE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMATIC REVIEW; TUBERCULOSIS;

EID: 33751381630     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200611000-00003     Document Type: Review

References (55)

1. Wolfe F, Zwilich S. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1072-1082.
2. Wolfe F, Michaud K. Fatigue, rheumatoid arthritis, and antitumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol. 2004;31(11):2115-2120.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at http://www.niams.nih.gov/hi/topics/arthritis/rahandout.htm; accessed March 14, 2006.
4. ACR. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46(2):328-346.
5. Arend WP. The innate immune system in rheumatoid arthritis. Arthritis Rheum. 2001;44(10):2224-2234.
6. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2(6):473-488.
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-916.
8. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43(12):2619-2633.
9. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350(25):2591-2602.
10. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903- 911.
11. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The efficacy and safety of adalimumab (Humira®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis (RA): 1- and 2-year results of the PREMIER study. Presentation: OP0013. Ann Rheum Dis. 2005;64(suppl 111):60.
12. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002;14(3):204-211.
13. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-1602.
14. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259.
15. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
16. Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol. 2002;20(5 suppl 27):S32-S34.
17. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761-1769.
18. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
19. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263-2271.
20. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932-1939.
21. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-681.
22. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-1593.
23. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478-486.
24. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196-2204.
25. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000;43(5):1001-1009.
26. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700-1721.
27. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 2004;6(suppl 2):S12-S18.
28. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003;15(3):226-236.
29. FDA. Arthritis Drugs Advisory Committee: safety update on TNF antagonists: infliximab and etanercept. Available at www.fda.gov/ohrms/dockets/ ac/01/briefing/3779b2.htm; accessed 12 May 2004.
30. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344(14):1099-1100.
31. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10):2565-2570.
32. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76(6):653-656.
33. Centocor. Remicade (infliximab) for IV injection. Prescribing information. Available at http://www.remicade.com/pdf/HCP_PPI.pdf; accessed November 13, 2005.
34. Wyeth. Enbrel (etanercept) for subcutaneous injection. Prescribing information. Available at www.humira.com; accessed October 13, 2005.
35. Abbott Laboratories Pharmaceutical Products Group. Humira (adalimumab) prescribing information; accessed November 13, 2005. Available at http://www.humira.com.
36. Kavanaugh AF, Cush JJ, Matteson E. American College of Rheumatology. Update on the Safety of New Drugs for Rheumatoid Arthritis. Part II: CHF, infection and other Safety Issues. Hotline. Presented at the FDA Meeting March 2003. Available at http://www.rheumatology.org/publications/hotline/0803chf.asp? aud=mem; accessed December 30, 2004.
37. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998;24(3):615-628.
38. Stone WJ. Comprehensive nursing approach to infliximab infusion therapy. J Infus Nurs. 2003;26(6):380-387.
39. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001;134(8):695-706.
40. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol. 2004;22(5 suppl 35):S115-S121.
41. Sidiropoulos P, Bertsias G, Kritikos HD, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis. 2004;63(2):144-148.
42. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis. 2003;62(12):1195-1198.
43. Bristol-Myers Squibb. ORENCIA (abatacept) prescribing information. Available at http://www.orencia.com; accessed January 17, 2006.
44. Genovese M, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
45. Moreland L, Kaine J, Espinoza L, et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo-controlled trials. Arthritis Rheum. 2005;52(suppl):350.
46. Kremer J, Westhovens R, Abud-Mendoza C, et al. Abatacept improves American College of Rheumatology responses and disease activity score 28 remission rates in both recent-onset and more established rheumatoid arthritis: results from the AIM trial. Arthritis Rheum. 2005;52(9 suppl):S562.
47. Kremer J, Genant H, Peterfy C, et al. Abatacept inhibits structural damage progression in recent-onset and more established rheumatoid arthritis: results from the AIM trial. Arthritis Rheum. 2005;52(9 suppl):S133.
48. Russell A, Kremer J, Zhou Y, et al. Abatacept induces sustained improvements in physical function and pain over 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate. Arthritis Rheum. 2005;52(9 suppl):S659.
49. Westhovens R, Kremer J, Shergy W, et al. DAS28 remission and clinical efficacy in rheumatoid arthritis patients with inadequate responses to methotrexate treated with abatacept: the phase III AIM trial and a phase IIb trial long-term extension. Arthritis Rheum. 2005;52(suppl):142.
50. Roche. Rituxan (rituximab) for IV injection. Prescribing information; accessed November 13, 2005.
51. van Vollenhoven R, Emery P, Fleischmann RM, et al. Safety and tolerability of rituximab in patients with moderate-to-severe rheumatoid arthritis (RA): results from the dose-ranging assessment international clinical evaluation of rituximab in RA (DANCER) study. Ann Rheum Dis. 2005;64(suppl 111):432.
52. Fleischmann R, Filipowicz-Sosnowska A, Li N, et al. Coadministration of glucocorticoids does not influence efficacy of, but reduces infusion reactions to, rituximab in rheumatoid arthritis: results from the DANCER study. Ann Rheum Dis. 2005;64(suppl 111):434.
53. Cohen S, Greenwald M, Dougados M, et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNFa therapies (REFLEX Study). Arthritis Rheum. 2005;52(suppl):677.
54. Hagihara K, Nishimoto N, Yoshizaki K. A humanized anti-IL-6 receptor antibody (MRA) in RA therapy. Nippon Rinsho. 2002;60(12):2401-2407.
55. Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 1998;95(14):8222-8226.